A citation-based method for searching scientific literature

Jennifer N Brudno, Irina Maric, Steven D Hartman, Jeremy J Rose, Michael Wang, Norris Lam, Maryalice Stetler-Stevenson, Dalia Salem, Constance Yuan, Steven Pavletic, Jennifer A Kanakry, Syed Abbas Ali, Lekha Mikkilineni, Steven A Feldman, David F Stroncek, Brenna G Hansen, Judith Lawrence, Rashmika Patel, Frances Hakim, Ronald E Gress, James N Kochenderfer. J Clin Oncol 2018
Times Cited: 290







List of co-cited articles
1017 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Noopur Raje, Jesus Berdeja, Yi Lin, David Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Ashley Turka,[...]. N Engl J Med 2019
493
75

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Adam D Cohen, Alfred L Garfall, Edward A Stadtmauer, J Joseph Melenhorst, Simon F Lacey, Eric Lancaster, Dan T Vogl, Brendan M Weiss, Karen Dengel, Annemarie Nelson,[...]. J Clin Invest 2019
223
62

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
Syed Abbas Ali, Victoria Shi, Irina Maric, Michael Wang, David F Stroncek, Jeremy J Rose, Jennifer N Brudno, Maryalice Stetler-Stevenson, Steven A Feldman, Brenna G Hansen,[...]. Blood 2016
411
43

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Wan-Hong Zhao, Jie Liu, Bai-Yan Wang, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei,[...]. J Hematol Oncol 2018
193
42

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
37

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Jie Xu, Li-Juan Chen, Shuang-Shuang Yang, Yan Sun, Wen Wu, Yuan-Fang Liu, Ji Xu, Yan Zhuang, Wu Zhang, Xiang-Qin Weng,[...]. Proc Natl Acad Sci U S A 2019
123
36

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R Verneris, Heather E Stefanski, Gary D Myers,[...]. N Engl J Med 2018
34

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Daniel W Lee, Bianca D Santomasso, Frederick L Locke, Armin Ghobadi, Cameron J Turtle, Jennifer N Brudno, Marcela V Maus, Jae H Park, Elena Mead, Steven Pavletic,[...]. Biol Blood Marrow Transplant 2019
600
29

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Zhiling Yan, Jiang Cao, Hai Cheng, Jianlin Qiao, Huanxin Zhang, Ying Wang, Ming Shi, Jianping Lan, Xiaoming Fei, Lai Jin,[...]. Lancet Haematol 2019
104
27

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Robert O Carpenter, Moses O Evbuomwan, Stefania Pittaluga, Jeremy J Rose, Mark Raffeld, Shicheng Yang, Ronald E Gress, Frances T Hakim, James N Kochenderfer. Clin Cancer Res 2013
331
26

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
972
26

Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, Pamela A Shaw, Richard Aplenc, David M Barrett, Nancy J Bunin, Anne Chew, Vanessa E Gonzalez, Zhaohui Zheng, Simon F Lacey,[...]. N Engl J Med 2014
26

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Cameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins, Colette Chaney, Sindhu Cherian, Xueyan Chen,[...]. Sci Transl Med 2016
538
25

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Nikhil C Munshi, Larry D Anderson, Nina Shah, Deepu Madduri, Jesús Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David Siegel, Albert Oriol,[...]. N Engl J Med 2021
104
25

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, Yongzhi K Cui, Cindy Delbrook, Steven A Feldman, Terry J Fry, Rimas Orentas, Marianna Sabatino, Nirali N Shah,[...]. Lancet 2015
24

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
Jae H Park, Isabelle Rivière, Mithat Gonen, Xiuyan Wang, Brigitte Sénéchal, Kevin J Curran, Craig Sauter, Yongzeng Wang, Bianca Santomasso, Elena Mead,[...]. N Engl J Med 2018
978
23

Current concepts in the diagnosis and management of cytokine release syndrome.
Daniel W Lee, Rebecca Gardner, David L Porter, Chrystal U Louis, Nabil Ahmed, Michael Jensen, Stephan A Grupp, Crystal L Mackall. Blood 2014
22

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
Cameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Theodore A Gooley, Sindhu Cherian, Michael Hudecek, Daniel Sommermeyer, Katherine Melville, Barbara Pender, Tanya M Budiarto,[...]. J Clin Invest 2016
952
21

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
575
19

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J Fry, Nirali N Shah, Rimas J Orentas, Maryalice Stetler-Stevenson, Constance M Yuan, Sneha Ramakrishna, Pamela Wolters, Staci Martin, Cindy Delbrook, Bonnie Yates,[...]. Nat Med 2018
548
19

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Marco L Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park, Kevin Curran, Stephen S Chung, Jolanta Stefanski, Oriana Borquez-Ojeda, Malgorzata Olszewska,[...]. Sci Transl Med 2014
19

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Stephen J Schuster, Jakub Svoboda, Elise A Chong, Sunita D Nasta, Anthony R Mato, Özlem Anak, Jennifer L Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel Landsburg,[...]. N Engl J Med 2017
758
19

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Eric L Smith, Kim Harrington, Mette Staehr, Reed Masakayan, Jon Jones, Thomas J Long, Khong Y Ng, Majid Ghoddusi, Terence J Purdon, Xiuyan Wang,[...]. Sci Transl Med 2019
93
20

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
Juliane Gust, Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, David Myerson, Luis F Gonzalez-Cuyar, Cecilia Yeung, W Conrad Liles, Mark Wurfel, Jose A Lopez,[...]. Cancer Discov 2017
510
19

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Sattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, William Wierda, Cristina Gutierrez, Frederick L Locke, Krishna V Komanduri, Yi Lin, Nitin Jain, Naval Daver,[...]. Nat Rev Clin Oncol 2018
836
18

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Bianca D Santomasso, Jae H Park, Darin Salloum, Isabelle Riviere, Jessica Flynn, Elena Mead, Elizabeth Halton, Xiuyan Wang, Brigitte Senechal, Terence Purdon,[...]. Cancer Discov 2018
281
17

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
David L Porter, Wei-Ting Hwang, Noelle V Frey, Simon F Lacey, Pamela A Shaw, Alison W Loren, Adam Bagg, Katherine T Marcucci, Angela Shen, Vanessa Gonzalez,[...]. Sci Transl Med 2015
929
16

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Cameron J Turtle, Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, Sindhu Cherian, Xueyan Chen, Brent Wood, Arletta Lozanski, John C Byrd, Shelly Heimfeld,[...]. J Clin Oncol 2017
323
16

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Joseph A Fraietta, Simon F Lacey, Elena J Orlando, Iulian Pruteanu-Malinici, Mercy Gohil, Stefan Lundh, Alina C Boesteanu, Yan Wang, Roddy S O'Connor, Wei-Ting Hwang,[...]. Nat Med 2018
475
16

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
James N Kochenderfer, Mark E Dudley, Sadik H Kassim, Robert P T Somerville, Robert O Carpenter, Maryalice Stetler-Stevenson, James C Yang, Giao Q Phan, Marybeth S Hughes, Richard M Sherry,[...]. J Clin Oncol 2015
16

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes.
Tea Gogishvili, Sophia Danhof, Sabrina Prommersberger, Julian Rydzek, Martin Schreder, Christian Brede, Hermann Einsele, Michael Hudecek. Blood 2017
98
16

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.
Max S Topp, Johannes Duell, Gerhard Zugmaier, Michel Attal, Philippe Moreau, Christian Langer, Jan Krönke, Thierry Facon, Alexey V Salnikov, Robin Lesley,[...]. J Clin Oncol 2020
114
16

Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Kevin M Friedman, Tracy E Garrett, John W Evans, Holly M Horton, Howard J Latimer, Stacie L Seidel, Christopher J Horvath, Richard A Morgan. Hum Gene Ther 2018
79
20

Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.
Carlos Fernández de Larrea, Mette Staehr, Andrea V Lopez, Khong Y Ng, Yunxin Chen, William D Godfrey, Terence J Purdon, Vladimir Ponomarev, Hans-Guido Wendel, Renier J Brentjens,[...]. Blood Cancer Discov 2020
37
43

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
Donald M O'Rourke, MacLean P Nasrallah, Arati Desai, Jan J Melenhorst, Keith Mansfield, Jennifer J D Morrissette, Maria Martinez-Lage, Steven Brem, Eileen Maloney, Angela Shen,[...]. Sci Transl Med 2017
579
15

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
Margot J Pont, Tyler Hill, Gabriel O Cole, Joe J Abbott, Jessica Kelliher, Alexander I Salter, Michael Hudecek, Melissa L Comstock, Anusha Rajan, Bharvin K R Patel,[...]. Blood 2019
83
18

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
James N Kochenderfer, Robert P T Somerville, Tangying Lu, Victoria Shi, Adrian Bot, John Rossi, Allen Xue, Stephanie L Goff, James C Yang, Richard M Sherry,[...]. J Clin Oncol 2017
282
15

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Nikoletta Lendvai, Douglas Sborov,[...]. Lancet Oncol 2020
189
15

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
Rebecca A Gardner, Olivia Finney, Colleen Annesley, Hannah Brakke, Corinne Summers, Kasey Leger, Marie Bleakley, Christopher Brown, Stephanie Mgebroff, Karen S Kelly-Spratt,[...]. Blood 2017
443
14

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
Norris Lam, Nathan D Trinklein, Benjamin Buelow, George H Patterson, Namrata Ojha, James N Kochenderfer. Nat Commun 2020
32
43

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Enli Liu, David Marin, Pinaki Banerjee, Homer A Macapinlac, Philip Thompson, Rafet Basar, Lucila Nassif Kerbauy, Bethany Overman, Peter Thall, Mecit Kaplan,[...]. N Engl J Med 2020
426
14

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn,[...]. N Engl J Med 2020
268
14

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Ujjawal H Gandhi, Robert F Cornell, Arjun Lakshman, Zhubin J Gahvari, Elizabeth McGehee, Megan H Jagosky, Ridhi Gupta, William Varnado, Mark A Fiala, Saurabh Chhabra,[...]. Leukemia 2019
128
14

Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Xiuli Wang, Miriam Walter, Ryan Urak, Lihong Weng, Christian Huynh, Laura Lim, ChingLam W Wong, Wen-Chung Chang, Sandra H Thomas, James F Sanchez,[...]. Clin Cancer Res 2018
69
18

CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.
Theodoros Giavridis, Sjoukje J C van der Stegen, Justin Eyquem, Mohamad Hamieh, Alessandra Piersigilli, Michel Sadelain. Nat Med 2018
415
13

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Stephan A Grupp, Michael Kalos, David Barrett, Richard Aplenc, David L Porter, Susan R Rheingold, David T Teachey, Anne Chew, Bernd Hauck, J Fraser Wright,[...]. N Engl J Med 2013
13

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Sagar Lonial, Meletios Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen,[...]. N Engl J Med 2015
838
13

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Nina Shah, Ajai Chari, Emma Scott, Khalid Mezzi, Saad Z Usmani. Leukemia 2020
72
18

BCMA is essential for the survival of long-lived bone marrow plasma cells.
Brian P O'Connor, Vanitha S Raman, Loren D Erickson, W James Cook, Lehn K Weaver, Cory Ahonen, Ling-Li Lin, George T Mantchev, Richard J Bram, Randolph J Noelle. J Exp Med 2004
660
13

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.
Eugenia Zah, Eunwoo Nam, Vinya Bhuvan, Uyen Tran, Brenda Y Ji, Stanley B Gosliner, Xiuli Wang, Christine E Brown, Yvonne Y Chen. Nat Commun 2020
37
35


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.